ChromaDex’s Niagen Demonstrates Safety, Efficacy in New Study

290

Los Angeles, CA—ChromaDex Corp. announced in a press release that a new study has further validated the safety and efficacy of ChromaDex’s proprietary form of nicotinamide riboside (NR), Niagen.

The press release notes that, besides being the largest study on NR to date, it is the first clinical trial to measure both the kinetics and dose dependent effects of chronic Niagen supplementation. The randomized, double-blind, placebo-controlled, parallel arm trial was performed on 132 healthy overweight adults. Daily doses of Niagen (at 100mg, 300mg, and 1000mg) initially increased, and then sustained, levels of NAD in the blood. On average, study participants consuming 300mg/day experienced a statistically significant 51% increase in whole blood NAD+ within two weeks, an increase maintained throughout the remainder of the eight-week study.

The press release says that all doses were well-tolerated, with no adverse events reported. No changes in LDL cholesterol levels or blood levels of homocysteine were observed.

Charles Brenner, Ph.D., chief scientific advisor at ChromaDex and head of biochemistry at the University of Iowa, said in the release: “This is a timely publication in the history of Niagen as it clearly shows safe, dose-dependent and time-dependent increases in blood NAD in human populations. These data will be used to design the next generation of trials to promote wellness as well as to test the activity of Niagen against diseases and conditions of metabolic stress.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here